Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Recommendation of “Hold” by Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has earned a consensus rating of “Hold” from the sixteen brokerages that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $29.3667.

A number of brokerages have recently issued reports on HIMS. JPMorgan Chase & Co. cut their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. TD Cowen dropped their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research report on Friday, March 27th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research note on Friday, May 22nd. Finally, Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $32.78 on Friday. The business’s 50-day moving average is $27.75 and its 200 day moving average is $26.41. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a market capitalization of $7.59 billion, a P/E ratio of -364.17, a P/E/G ratio of 46.74 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same period in the prior year, the company posted $0.20 EPS. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, equities research analysts forecast that Hims & Hers Health will post 0.05 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the transaction, the chief financial officer directly owned 281,867 shares of the company’s stock, valued at $7,300,355.30. The trade was a 11.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This represents a 3.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 163,973 shares of company stock worth $4,859,194. 11.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after acquiring an additional 1,407,651 shares during the last quarter. Capital World Investors raised its position in shares of Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares during the period. State Street Corp raised its position in shares of Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after buying an additional 132,311 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.